Interstitial Pneumonia Risk Diagnosis in Cancer Immunotherapy

Biomarkers for prediction and diagnosis of interstitial pneumonia, a side effect of cancer treatment with immune checkpoint inhibitors


  • Screening of patients at high risk of developing interstitial pneumonia
  • Detected by ELISA from blood samples


Currently, immune checkpoint inhibitors (ICBs) like PD-1 inhibitors are used to treat various types of cancer, but their side effects, immune-related adverse events (irAEs), have become a serious problem. Ideally, ICB should activate only the anti-tumor immune response, attacking cancer cells while leaving normal cells unaffected. However, ICB sometimes activates the immune response against normal cells (autoimmune response), which is the cause of irAE. Based on prognostic studies of patients treated with PD-1 inhibitors, we revealed that interstitial pneumonia, one of irAEs, was frequently observed in patients with specific HLA types, and comprehensive analysis for 23,000 antigens presented by the patients’ HLA identified specific antigens that induced interstitial pneumonia. Antibody responses against the antigens became biomarkers for risk determination.



International Patent Pending


Hiroyoshi NISHIKAWA Prof. (Tokai National Higher Education and Research System Nagoya University, Graduate School of Medicine)

Current Stage

  •  Currently analyzing clinical samples, but need to establish more accurate ELISA
  • We are looking for partners to help establish ELISA and develop commercial kit products.

Product No: BK-02998

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name


Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.


Our support is provided free of charge.
The information submitted on this form is for business development use only.

By clicking "Send", you are agreeing to our Privacy Policy.
If you have questions please reach out to info (at)

About Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.